Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Other Non Operating Income (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Other Non Operating Income for 11 consecutive years, with $253.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non Operating Income fell 98.33% year-over-year to $253.0, compared with a TTM value of -$337359.0 through Sep 2025, down 214.02%, and an annual FY2024 reading of -$44082.0, down 17892.65% over the prior year.
  • Other Non Operating Income was $253.0 for Q3 2025 at Sunshine Biopharma, down from $1940.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $286535.0 in Q2 2024 and bottomed at -$340003.0 in Q4 2024.
  • Average Other Non Operating Income over 5 years is -$2941.2, with a median of $22.0 recorded in 2022.
  • Peak annual rise in Other Non Operating Income hit 109883.52% in 2024, while the deepest fall reached 871702.56% in 2024.
  • Year by year, Other Non Operating Income stood at -$7845.0 in 2021, then tumbled by 44.4% to -$11328.0 in 2022, then soared by 99.66% to -$39.0 in 2023, then plummeted by 871702.56% to -$340003.0 in 2024, then skyrocketed by 100.07% to $253.0 in 2025.
  • Business Quant data shows Other Non Operating Income for SBFM at $253.0 in Q3 2025, $1940.0 in Q2 2025, and $451.0 in Q1 2025.